Pantostad 40 CAP

Rx

Indications

• Gastro-oesophageal reflux disease (GORD).
• Peptic ulcer disease.
• Prophylaxis for NSAID-associated ulceration.
• Pathological hypersecretory states (Zollinger-Ellison syndrome).

Dosage

• Gastro-oesophageal reflux disease (GERD): 20 – 40 mg once daily x 4 – 8 weeks. Maintenance therapy: 20 to 40 mg daily. Recurring therapy: 20 mg daily.
• Peptic ulcer disease: 
  40 mg once daily x 2 – 4 weeks (duodenal ulceration) or 4 – 8 weeks (benign gastric ulceration).
  For the eradication of Helicobacter pylori: Pantoprazole (40 mg twice daily) + clarithromycin (500 mg twice daily) + amoxicillin (1 g twice daily) or metronidazole (400 mg twice daily).
• Prophylaxis for NSAID-associated ulceration: 20 mg daily.
• Zollinger-Ellison syndrome: The initial dose is 80 mg daily, adjusted as required, up to 240 mg daily. Daily doses greater than 80 mg should be given in 2 divided doses.
• Hepatic impairment: Reduce dosage (maximum 20 mg daily) or use on alternate days (40 mg daily).
• Renal impairment: A maximum dose of 40 mg daily.

Usage

• Administered orally. Once-daily doses should be taken in the morning.

• Known hypersensitivity to any other ingredient in the formulation.

Diarrhoea, hyperglycemia, headache, abdominal pain, liver function tests abnormalities.

• Symptomatic response to therapy with pantoprazole does not preclude the presence of gastric neoplasm.
• Mild, transient elevations of serum ALT (SGPT).
• Pantoprazole may lead to malabsorption of cyanocobalamin.
• Safety and efficacy in children younger than 18 years of age have not been established.
• Pregnant and nursing women (discontinue nursing or the drug).
• Driving/ operating machines.